[Report] Daiichi Sankyo: Pipeline, Products, Performance, Potential TOC

EXECUTIVE SUMMARY

Introduction
Financial Performance 2005
- Sales and Market Position
- Income
  - Operating Income By Business Area - Daiichi
  - Operating Income by Business Area - Daiichi
  - Operating Income By Business Area - Sankyo
  - Operating Income by Business Area - Sankyo
- Expenditure
  - Capital Expenditure
  - Capital Expenditure By Business Area - Daiichi
  - Capital Expenditure by Business Area - Daiichi
  - Capital Expenditure By Business Area - Sankyo
  - Capital Expenditure by Business Area - Sankyo
  - R&D Expenditure
- Divisional Performance
  - Sales By Business Area - Daiichi
  - Sales By Business Area - Daiichi
  - Sales By Business Area - Sankyo
  - Sales by Business Area - Sankyo
  - Total Assets By Business Area - Daiichi
  - Total Assets By Business Area - Daiichi
  - Total Assets By Business Area - Sankyo
  - Total Assets by Business Area - Sankyo
- Geographic Performance
  - Sales By Destination - Sankyo
  - Sales by Destination - Sankyo
  - Sales By Origin - Daiichi
  - Sales By Origin - Daiichi
  - Sales By Origin - Sankyo
  - Sales By Origin - Sankyo
  - Operating Income By Geographical Area - Sankyo
  - Total Assets By Geographical Area - Sankyo
Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Employees
Product/R&D Overview
- Key Products
  - Recent Product Launches
  - Recent Product Approvals
  - Discontinued Products
- R&D Strategy
  - Key R&D Projects
- R&D Pipeline Overview
  - Discontinued R&D Projects
- Sales Forecast
  - Sales of Major Products (2000A-2010E)
Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

Major Products, Therapeutic Areas and Sales
Top Selling Products, 2005
R&D Pipeline - Japan

Cardiovascular - Products
- Major Launched Products
- Acecol
  - Sales
  - Competitor Products
  - Sales Forecast
- Acecol Sales (2000A-2010E)
- Artist
  - Sales
  - Competitor Products
  - Sales Forecast
- Artist Sales (2000A-2010E)
- Calblock
  - Sales
- Coversyl (DW-7950)
  - Sales
  - Key Markets/Indications
  - Clinical Trial Results
- HANP Injection
- Livalo
  - Sales
- Mevalotin/Pravachol
  - Sales
  - Key Markets/Indications
  - Further Development
  - Competitor Products
  - Generic Competition
  - Sales Forecast
- Mevalotin Sales (2000A-2010E)
- Olmetec/Benicar
  - Sales
  - Markets/Indications
  - Further Development
  - Competitor Products
  - Sales Forecast
- Olmetec/Benicar Sales (2000A-2010E)
  - Clinical Trial Results
- Panaldine
  - Sales
  - Safety Issues
  - Competitor Products
  - Sales Forecast
- Panaldine Sales (2000A-2010E)
- Sunrythm
  - Sales
  - Competitor Products
- WelChol
  - Sales
  - Key Markets/Indications
  - Further Development
  - Clinical Trial Results
Cardiovascular - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- Adenoscan
- CS-3030
- DU-176b
- DZ-697b
- HGF DNA plasmid
- KAI-9803
- Prasugrel (CS-747, LY640315)
  - Clinical Trial Results
- SUN N4057
- SUN N8075
Cardiovascular - Summary
- Growth Potential
- Limiting Factors
Metabolism - Products
- Major Launched Products
- Fastic
  - Sales
  - Markets/Indications
  - Further Development
- Others
Metabolism - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- CS-011
- CS-872
- CS-917 (R-132917)
  - Development Status
- Fidarestat (SNK-860)
- SUN E7001
Metabolism - Summary
- Growth Potential
- Limiting Factors
Infection - Products
- Major Launched Products
- Banan
  - Sales
  - Key Markets/Indications
  - Generic Competition
  - Sales Forecast
- Banan Sales (2000A-2010E)
- Carbenin
  - Sales
  - Sales Forecast
- Carbenin Sales (2000A-2010E)
- Cravit
  - Sales
  - Key Markets/Indications
  - Lawsuits/Generic Competition
  - Sales Forecast
- Cravit Sales (2000A-2010E)
Infection - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- Act-HIB (DF-098)
- CS-023
- CS-3955
- CS-758
- CS-8958 (R118958)
- DX-619
- Faropenem medoxomil
- Gracevit (DU-6859a)
Infection - Summary
- Growth Potential
- Limiting Factors
Cancer - Products
- Topotecin
  - Key Markets/Indications
  - Further Development
Cancer - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- CS-706 (R-109339)
- CS-1008 (R-161460)
- CS-7017 (RS-5444)
- TZT-1027
- DJ-927
Cancer - Summary
Immunity and Allergy - Products
- Major Launched Products
- Alesion
  - Sales
  - Sales Forecast
- Alesion Sales (2000A-2010E)
- Zyrtec
  - Sales
  - Key Markets/Indications
  - Competitor Products
  - Sales Forecast
- Zyrtec Sales (2000A-2010E)
Immunity and Allergy - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- CS-0777
- CS-502
- CS-712 (R-133663)
- CS-9507 (R-125224)
- DW-908e
- Xolair (omalizumab, IGE025)
Immunity and Allergy - Summary
- Growth Potential
- Limiting Factors
Bone and Joints - Products
- Major Launched Products
- Loxonin
  - Sales
  - Key Markets/Indications
  - Further Development
  - Competitor Products
  - Sales Forecast
- Loxonin Sales (2000A-2010E)
- Mobic
Bone and Joints - R&D
- R&D Pipeline - Japan
- OCIF (R-142440)
- SUN E3001
Bone and Joints - Summary
Other - Products
- Major Launched Products
- Feron
- Kremezin
  - Sales
- Omnipaque
  - Sales
  - Sales Forecast
- Omnipaque Sales (2000A-2010E)
- Zantac
  - Sales
  - Sales Forecast
- Zantac Sales (2000A-2010E)
Others - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- CS-088
- CS-526 (R-105266)
- CS-801
- CS-1401E
- Dopascan
- DL-404
- Sonazoid
- SUN11031
- SUN0588r
- SUN-Y7017
  - Clinical Trial Results
- Urief

APPENDIX 1 - FINANCIAL PERFORMANCE

Full Year Results - Proforma
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
Full Year Results 2005 - Daiichi
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- Research Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
Full Year Results 2005 - Sankyo
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity

APPENDIX 2 - KEY AGREEMENTS

A Menarini Industrie Farmaceutiche Riunte SrL
- 16th March 2001
Amersham Health
- 19th March 1998
AnGes MG Inc
- January 2001
- 9th April 2002
Astellas Pharma Inc
- 2nd June 2003
- 27th August 2004
BioMarin Pharmaceutical Inc
- 23rd November 2004
- 5th May 2005
BioMimetic Pharmaceuticals Inc (BMP)
- 8th January 2004
Biota Holdings Limited
- 3rd October 2003
Boehringer Ingelheim
Cyclacel Limited
- 5th December 2003
Eli Lilly
- 20th December 2000
Forest Laboratories Inc
- 12th December 2001
GelTex Pharmaceuticals Inc
- 23rd December 1999
GlaxoSmithKline
- 2nd November 2001
- 27th January 2003
Kissei Pharmaceutical Co Ltd
- 14th March 2001
Kureha Chemical Industry Co Ltd
- March 2001
Kyoto Pharmaceutical Industries Ltd
Metabasis Therapeutics Inc
- 18th December 1997
- 11th January 1999
- 29th October 2002
- 8th April 2004
Novartis
- 8th October 2003
Pfizer
- 18th May 1999
- 29th May 2000
Pharmacopeia Inc
- 3rd February 2003
- 2nd December 2003
Roche
- 10th November 2003
sanofi-aventis
- July 1993
- 13th February 2003
- 5th July 2005
Sanwa Kagaku Kenkyusho
- 9th January 2004
Schering-Plough
- 4th August 2005
Suntory Ltd
- 19th March 2002
Teikoku Hormone Mfg Co Ltd
- 11th December 2000
Ube Industries Ltd
University of Alabama
Zeria Pharmaceutical Co Ltd
- 1st April 2003

APPENDIX 3 - KEY PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES

Subsidiaries
Joint Ventures

Daiichi Sankyo: Pipeline, Products, Performance, Potential

Table of Contents

EXECUTIVE SUMMARY

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

APPENDIX 1 - FINANCIAL PERFORMANCE

APPENDIX 2 - KEY AGREEMENTS

APPENDIX 3 - KEY PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES

APPENDIX 4 - PRODUCT INDEX